Update Your Colistin and Polymyxin B Protocols

You'll see more focus on optimizing polymyxin antibiotics...due to new guidelines from the Infectious Diseases Society of America and others.

IV colistin (polymyxin E) and polymyxin B have been around for decades. But nephrotoxicity concerns limit their use.

Now we're reaching for polymyxins more often due to increases in multidrug-resistant (MDR) gram-negative organisms, such as carbapenem-resistant Enterobacteriaceae or some Pseudomonas or Acinetobacter.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote